The co-development study combines AAX Biotech’s Seqitope platform with ToxoTech’s expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision, the two companies describe. By applying Seqitope to optimize receptor recognition, the collaboration aims to generate novel variants with potential as treatments for neuromuscular and neurological indications. 

“This project represents an exciting new application of Seqitope beyond its established use in antibody epitope mapping,” says Daniel X. Johansson, CEO/CSO of AAX Biotech.

“Working together with AAX Biotech allows us to accelerate the development of innovative therapies with the potential to transform treatment options across neurological and neuromuscular indications”, says Geoffrey Masuyer, CEO of ToxoTech.